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Abstract (57 words) 
 Living-donor lobar lung transplantation was performed in a 10-year-old boy with bronchiolitis 
obliterans (BO) after bone marrow transplantation (BMT) for recurrent acute myeloid leukemia (AML). 
He developed posterior reversible encephalopathy syndrome (PRES) due to calcineurin inhibitor (CNI) 
postoperatively, which was recovered with suspension of CNI. PRES should be considered one of the 
important morbidity after lung transplantation. 
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Introduction  
 Posterior reversible encephalopathy syndrome (PRES) is a relatively new clinico-radiological entity 
and one of important side effects of calcineurin inhibitor (CNI). Herein we report a case of PRES induced 
by CNI after living-donor lobar lung transplantation (LDLLT) in a 10-year-old boy with bronchiolitis 




A 6-year-old boy was diagnosed with AML in 2005 and treated with chemotherapy. In May 2008, at the 
age of 9, he underwent BMT from an unrelated, HLA-identical and ABO-mismatched donor for recurrent 
AML. Tacrolimus was administered intravenously then orally after BMT and stopped in September, 2008, 
since no acute graft versus host diseases (GVHD) occurred. The blood trough concentration of tacrolimus 
after BMT was maintained in a range between 10.7 and 23.9 ng/mL. In February 2009, he was diagnosed 
as having BO, as a pulmonary manifestation of chronic GVHD after BMT. In March 2009, sixteen days 
after the initiation of low dose oral tacrolimus treatment (1.0 mg/day) for BO, he lost consciousness and 
developed convulsion, hypertension (178 mmHg in systolic pressure), and paralysis with respiratory 
arrest requiring mechanical ventilation. The laboratory test revealed the white blood cells count to be 8.5 
x 109 /l and serum level of C-reactive protein to be below 0.09 mg/dl and his body temperature to be 
36.6 °C on the day of symptom onset. Magnetic resonance imaging (MRI) of the brain demonstrated 
multiple focal areas of hyperintensity on both T2-weighted and FLAIR (fluid attenuated inversion 
recovery) images, predominantly in the white and gray matter of the occipital and posterior parietal lobes 
(Fig 1A, B). He was diagnosed as having PRES due to tacrolimus neurotoxity. The blood trough 
concentration of tacrolimus was 8.4 ng/mL at the onset of PRES. The administration of tacrolimus was 
stopped immediately, and the symptoms rapidly and completely disappeared. MRI abnormalities 
gradually improved. After improvement of PRES, cyclosporine was re-initiated in April 2009, to treat BO. 
Under treatment with cyclosporine and steroid, however, his respiratory condition worsened and 
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continuous oxygen inhalation was initiated in September 2009, at the age of 10 and 3 months. His 
respiratory status further deteriorated because of BO progression with respiratory Pseudomonous 
Aeruginosa infection.  
The patient was transferred to Kyoto University Hospital in January 2010. On admission, his vital 
capacity was 0.72 L (39.6% predicted), FEV1 was 0.27L (16.3% predicted), and arterial blood gas 
demonstrated a pH of 7.40, PaO2 of 87.0 mmHg, and PaCO2 of 55.8 mmHg with 2L/min oxygen 
administered via nasal cannula. The blood trough concentration of cyclosporine on admission was 72 
ng/ml and the systemic/diastolic blood pressure was 120/62 mmHg. 
Cadaveric lung transplantation was not a realistic option because brain death was legally accepted only 
for those older than 15 years old in Japan at that time. His parents, mother, 43 years old, and father, 44 
years old, offered to be lung donors.  
In February 2010, he underwent living-donor lobar lung transplantation with a left lower lobe from his 
mother and a right lower lobe from his father. The surgical aspects of the donor lobectomy, donor 
backtable preservation technique, and recipient bilateral pneumonectomy and lobar implantation have 
been previously described by Starnes’ group 1. The patient was completely weaned from the ventilator on 
postoperative day (POD) 3. After lung transplantation, immnunosuppressive therapy consisted of oral 
cyclosporine (target trough level: 250 -350 ng/ml), mycophenolate mofetil and prednisolone. 
On POD 12, he complained of visual disturbance and brain MRI on that day demonstrated multiple 
focal areas of hyperintensity in both T2-weighted and FLAIR images, predominantly in the white and 
gray matter of the occipital and parietal lobes (Fig. 1C, D). The systemic/diastolic blood pressure was 
157/108 mmHg, and the blood trough concentration of cyclosporine on POD 9 and POD 12 (on set of 
PRES) was 569 and 382 ng/ml, respectively. The laboratory test revealed the white blood cells count to 
be 8.1 x 109 /l and serum level of C-reactive protein to be 1.7 mg/dl and his body temperature to be 
37.3 °C on the day of symptom onset.  He was diagnosed as having recurrent PRES due to cyclosporine 
this time. Therefore, cyclosporine administration was stopped and enalapril maleate (inhibitor of 
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angiotensin converting enzyme) was started to reduce blood pressure. For immunosuppression after 
lung transplantation, basiliximab was administered on POD 13 and 17, replacing cyclosporine. 
Mycophenolate mofetil and prednisolone administration was continued with same dose as that at the onset 
of PRES. After withdrawal of cyclosporine, cyclosporine concentration gradually decreased, and his 
visual symptoms were completely resolved on POD 15, which was 3 days after diagnosis and the start of 
treatment for PRES. Cyclosporine was restarted on POD 20 at a low dose. The brain MRI on POD 55 
demonstrated that the lesion was improving (Fig. 1E, F). He was discharged from the hospital on POD 75 
and now 11 months postoperatively, he has returned to a normal life without oxygen inhalation and is 
able to perform daily activities without visual symptoms. Under careful observation after restarting the 




 PRES is a relatively new clinico-radiological entity first described as reversible posterior 
leukoencephalopathy syndrome in 1996. 2 Originally, it denoted a reversible predominantly posterior 
leukoencephalopathy in patients with renal insufficiency, hypertension or immunosuppression. Classic 
neuroimaging in such patients shows edema involving the white matter in the posterior portions of the 
cerebral hemispheres, especially bilaterally in the parieto-occipital regions. The varieties of symptoms in 
PRES include headache, altered mentation, convulsion, unconsciousness, and visual disturbance.  
 Although the pathogenesis of PRES has not yet been sufficiently clarified, it is thought to involve 
vasogenic edema.3 When the systemic blood pressure increases above certain level, the autoregulation 
system that stabilizes brain blood flow fails and hyperperfusion results in leakage of blood plasma into 
the interstitium in the brain. The development of PRES under treatment with CNI is also thought to 
correlate with endothelial cell injury by CNI. In addition, it is possible that CNI agent may induce 
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hypertension, which may result in PRES 4. Thus, PRES is an important morbidity after transplantation 
and the administration of CNI as an immunosuppressant. 
 Treatment for PRES mainly consists of controlling hypertension and convulsion. If the patient is 
administered CNI, the CNI should be discontinued, then restarted at a lower dose after improvement of 
symptoms, or converted (e.g. from tacrolimus to cyclosporine, or from cyclosporine to tacrolimus). The 
prognosis of PRES is generally considered reversible and benign; however, prolonged seizures, 
hypertension, or both may result in permanent neurological deficit and cerebral infarction 5. Thus, 
appropriate and early diagnosis and treatment of PRES is highly critical. 
 The present patient experienced two episodes of PRES after different treatments for different diseases. 
The first episode occurred sixteen days after the initiation of low dose tacrolimus treatment for BO. 
Before that, he had already received tacrolimus after BMT without any symptoms of PRES, and had 
shown a higher trough concentration of tacrolimus than that at PRES onset. The second episode occurred 
twelve days after lung transplantation. He had been on cyclosporine preoperatively to treat BO and 
postoperatively after lung transplantation, with a relatively higher trough concentration on the day of 
PRES onset. For immunosuppressive maintenance after withdrawal of cyclosporine after lung 
transplantation, we did not use methylprednisolone after development of PRES because 
methylprednisolone administration was considered to be one of risk factor in the development of 
PRES 
2, 6
. In the present case, blood pressure was high at onset of each episode, but the blood 
concentration of CNI did not seem to play a major role in the development of PRES. We speculate that 
the development both the first and second episodes of the PRES in the present patient correlated with CNI 
and hypertension as well as the patient’s circumstance. The first episode occurred after BMT with chronic 
GVHD, in which endothelial injury by several cytokines was likely to have occurred during engraftment 
of bone marrow graft. The second episode occurred during the acute phase after lung transplantation, in 
which cytokines were also likely to have been activated. Horbinski et al. reported a case of PRES after 
cardiac transplantation and demonstrated endothelial activation, selective intravascular and perivascular 
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T-cell trafficking, and VEGF expression in astrocytes, neurons, and the endothelium histologically in 
brain biopsy specimens obtained to rule out brain infection. 7 
 PRES after thoracic transplantation was rarely reported 7, but Bartynski et al. reported a institutional 
retrospective study of PRES after solid organ transplantation. In their study, PRES developed in 21 
(0.49%) of 4,222 patients who underwent solid organ transplantation, and 3 (0.64%) of 468 lung 
transplantation recipients developed PRES. 8 
 In conclusion, we demonstrated PRES due to the neurotoxity of different CNI developed twice in one 
patient. Both clinical symptoms and MRI findings were reversible and treatable with early diagnosis and 
immediate treatment including discontinuation or conversion of CNI. PRES should be considered in 
patients showing loss of consciousness, convulsion, or visual disturbance accompanied by hypertension 
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Figure Legend  
  
Figure 1.  
Axial MRI FLAIR images of the present patient at onset of PRES in March 2009 during treatment of BO 
with tacrolimus (A, B), and in February 2010, POD 13 after lung transplantation with cyclosporine 
administration (C, D). Patchy areas of  high signal intensity (arrows) were demonstrated in the bilateral 
occipital, parietal and temporal lobes. On FLAIR images (E, F) obtained 6 weeks after PRES onset, the 
signal intensity was significantly diminished. 
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